Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory biomarker study of nivolumab with or without ipilimumab in advanced melanoma
NL-OMON41223Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in melanoma (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Pharmacodynamic biomarker activity. Started Jul 2014; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON41223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41223.